Treatment-shortening regimens for tuberculosis: updates and future priorities
In the past 2 years, remarkable advances have been made in shortening tuberculosis (TB) treatment. In particular, four clinical trials (Study 31/A5349, Nix-TB, ZeNix and TB-PRACTECAL) have provided evidence of the efficacy of regimens based on new and repurposed drugs: the 4-month regimen for drug-s...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Respiratory Society
2023-09-01
|
| Series: | Breathe |
| Online Access: | http://breathe.ersjournals.com/content/19/3/230028.full |
| _version_ | 1797448503645962240 |
|---|---|
| author | Francesca Saluzzo Victor Abiola Adepoju Raquel Duarte Christoph Lange Patrick P.J. Phillips |
| author_facet | Francesca Saluzzo Victor Abiola Adepoju Raquel Duarte Christoph Lange Patrick P.J. Phillips |
| author_sort | Francesca Saluzzo |
| collection | DOAJ |
| description | In the past 2 years, remarkable advances have been made in shortening tuberculosis (TB) treatment. In particular, four clinical trials (Study 31/A5349, Nix-TB, ZeNix and TB-PRACTECAL) have provided evidence of the efficacy of regimens based on new and repurposed drugs: the 4-month regimen for drug-susceptible TB, and the 6-month bedaquiline–pretomanid–linezolid regimen with or without moxifloxacin for multidrug-resistant/rifampicin-resistant TB. Even if the evidence at the basis of these new regimens is compelling, several questions remain open, particularly concerning linezolid dose finding, the upsurging threat of bedaquiline-resistant Mycobacterium tuberculosis and the feasibility of applying these results to the paediatric population. Several ongoing trials may fill the remaining gaps and produce further reliable evidence to address the outstanding questions in TB treatment shortening. |
| first_indexed | 2024-03-09T14:12:21Z |
| format | Article |
| id | doaj.art-f4185890d03a4cf99b52723be2005081 |
| institution | Directory Open Access Journal |
| issn | 1810-6838 2073-4735 |
| language | English |
| last_indexed | 2024-03-09T14:12:21Z |
| publishDate | 2023-09-01 |
| publisher | European Respiratory Society |
| record_format | Article |
| series | Breathe |
| spelling | doaj.art-f4185890d03a4cf99b52723be20050812023-11-29T09:39:13ZengEuropean Respiratory SocietyBreathe1810-68382073-47352023-09-0119310.1183/20734735.0028-20230028-2023Treatment-shortening regimens for tuberculosis: updates and future prioritiesFrancesca Saluzzo0Victor Abiola Adepoju1Raquel Duarte2Christoph Lange3Patrick P.J. Phillips4 Vita-Salute San Raffaele University, Milan, Italy Department of HIV and Infectious Diseases, Jhpiego (an affiliate of Johns Hopkins University), Abuja, Nigeria EPI Unit, Instituto de Saúde Pública da Universidade do Porto, Porto, Portugal Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany University of California, San Francisco, Center for Tuberculosis, San Francisco, CA, USA In the past 2 years, remarkable advances have been made in shortening tuberculosis (TB) treatment. In particular, four clinical trials (Study 31/A5349, Nix-TB, ZeNix and TB-PRACTECAL) have provided evidence of the efficacy of regimens based on new and repurposed drugs: the 4-month regimen for drug-susceptible TB, and the 6-month bedaquiline–pretomanid–linezolid regimen with or without moxifloxacin for multidrug-resistant/rifampicin-resistant TB. Even if the evidence at the basis of these new regimens is compelling, several questions remain open, particularly concerning linezolid dose finding, the upsurging threat of bedaquiline-resistant Mycobacterium tuberculosis and the feasibility of applying these results to the paediatric population. Several ongoing trials may fill the remaining gaps and produce further reliable evidence to address the outstanding questions in TB treatment shortening.http://breathe.ersjournals.com/content/19/3/230028.full |
| spellingShingle | Francesca Saluzzo Victor Abiola Adepoju Raquel Duarte Christoph Lange Patrick P.J. Phillips Treatment-shortening regimens for tuberculosis: updates and future priorities Breathe |
| title | Treatment-shortening regimens for tuberculosis: updates and future priorities |
| title_full | Treatment-shortening regimens for tuberculosis: updates and future priorities |
| title_fullStr | Treatment-shortening regimens for tuberculosis: updates and future priorities |
| title_full_unstemmed | Treatment-shortening regimens for tuberculosis: updates and future priorities |
| title_short | Treatment-shortening regimens for tuberculosis: updates and future priorities |
| title_sort | treatment shortening regimens for tuberculosis updates and future priorities |
| url | http://breathe.ersjournals.com/content/19/3/230028.full |
| work_keys_str_mv | AT francescasaluzzo treatmentshorteningregimensfortuberculosisupdatesandfuturepriorities AT victorabiolaadepoju treatmentshorteningregimensfortuberculosisupdatesandfuturepriorities AT raquelduarte treatmentshorteningregimensfortuberculosisupdatesandfuturepriorities AT christophlange treatmentshorteningregimensfortuberculosisupdatesandfuturepriorities AT patrickpjphillips treatmentshorteningregimensfortuberculosisupdatesandfuturepriorities |